FY2018 EPS Estimates for Sol Gel Technologies Ltd Lifted by Analyst (SLGL)
Sol Gel Technologies Ltd (NASDAQ:SLGL) – Jefferies Financial Group raised their FY2018 earnings per share estimates for Sol Gel Technologies in a research note issued on Thursday, November 15th. Jefferies Financial Group analyst D. Steinberg now expects that the company will post earnings per share of ($1.89) for the year, up from their prior estimate of ($1.99). Jefferies Financial Group also issued estimates for Sol Gel Technologies’ Q4 2018 earnings at ($0.71) EPS.
Sol Gel Technologies (NASDAQ:SLGL) last issued its quarterly earnings data on Tuesday, November 13th. The company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.16. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.05 million.
Shares of Sol Gel Technologies stock opened at $6.74 on Monday. The stock has a market cap of $132.46 million and a price-to-earnings ratio of -1.34. Sol Gel Technologies has a 1-year low of $5.98 and a 1-year high of $16.48.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James & Associates bought a new stake in shares of Sol Gel Technologies during the second quarter valued at approximately $102,000. Alpine Global Management LLC bought a new stake in shares of Sol Gel Technologies during the second quarter valued at approximately $118,000. Delek Group Ltd. grew its stake in shares of Sol Gel Technologies by 22.3% during the second quarter. Delek Group Ltd. now owns 1,269,816 shares of the company’s stock valued at $9,803,000 after purchasing an additional 231,786 shares during the last quarter. Finally, Guggenheim Capital LLC bought a new stake in shares of Sol Gel Technologies during the first quarter valued at approximately $1,073,000. 22.27% of the stock is currently owned by institutional investors and hedge funds.
Sol Gel Technologies Company Profile
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Featured Article: What are defining characteristics of a correction?
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.